Page last updated: 2024-10-25

debrisoquin and Peripheral Nervous System Diseases

debrisoquin has been researched along with Peripheral Nervous System Diseases in 3 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.

Research Excerpts

ExcerptRelevanceReference

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shah, RR2
Oates, NS2
Idle, JR2
Smith, RL2
Lockhart, JD2
Harland, CC1
Steventon, GB1
Marsden, JR1

Other Studies

3 other studies available for debrisoquin and Peripheral Nervous System Diseases

ArticleYear
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.
    British medical journal (Clinical research ed.), 1982, Jan-30, Volume: 284, Issue:6312

    Topics: Adult; Aged; Alcohol Drinking; Angina Pectoris; Debrisoquin; Female; Humans; Isoquinolines; Liver Fu

1982
Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.
    American heart journal, 1983, Volume: 105, Issue:1

    Topics: Angina Pectoris; Debrisoquin; Electromyography; Humans; Hydroxylation; Isoquinolines; Male; Middle A

1983
Thalidomide-induced neuropathy and genetic differences in drug metabolism.
    European journal of clinical pharmacology, 1995, Volume: 49, Issue:1-2

    Topics: Acetylation; Adrenergic Agents; Adult; Anti-Infective Agents; Debrisoquin; Dermatologic Agents; Fema

1995